Results to be shared at Biotech Showcase during JP Morgan conference week in San Francisco and at BI0-CEO in New York
An advanced CPB liver cancer patient remains clear of cancer 6 years following treatment with Namodenoson
While CPB patients are typically excluded from liver cancer clinical studies due to low expected response rates, Namodenoson-treated CPB7 patients had statistically significant overall survival gain
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.